Active substanceCalcium gluconateCalcium gluconate
Similar drugsTo uncover
  • Calcium gluconate
    pills inwards 
    ATOLL, LLC     Russia
  • Calcium gluconate
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    pills inwards 
  • Calcium gluconate
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Calcium gluconate
    pills inwards 
  • Calcium gluconate
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Calcium gluconate
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Calcium gluconate
    solution w / m in / in 
    BINNOFARM, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
    TRIM, LLC     Russia
  • Calcium gluconate
    pills inwards 
    LYUMI, LLC     Russia
  • Calcium gluconate
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
    DALHIMFARM, OJSC     Russia
  • Calcium gluconate
    pills inwards 
    MEDISORB, CJSC     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    solution w / m in / in 
    ESKOM NPK, OAO     Russia
  • Calcium gluconate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Calcium gluconate
    solution w / m in / in 
  • Calcium gluconate
    solution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Calcium gluconate, stabilized
    solution for injections 
    FARMAK, PAO     Ukraine
  • Calcium gluconate, stabilized
    solution w / m in / in 
  • Calcium gluconate Extrabate
    pills inwards 
  • Calcium gluconate-Vial
    solution w / m in / in 
    VIAL, LLC     Russia
  • Calcium gluconate-lekT
    pills inwards 
  • Calcium gluconate-SOLOfarm
    solution w / m in / in 
    GROTEKS, LLC     Russia
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    Active substance:

    calcium gluconate monohydrate - 100 mg

    Excipients:

    calcium hydroxide 5 mg

    lactic acid - 0.5 mg

    water for injection - up to 1 ml

    Description:

    Transparent colorless liquid.

    Pharmacotherapeutic group:Calcium-phosphorus exchange regulator
    ATX: & nbsp

    A.12.A.A.03   Calcium gluconate

    A.12.A.A   Calcium preparations

    Pharmacodynamics:

    The preparation of calcium replenishes the deficiency of calcium ions, which are necessary for carrying out the process of transmission of nerve impulses, reduction of skeletal and smooth muscles, myocardial activity, formation of bone tissue, and clotting of blood.

    With intravenous injection stimulates the sympathetic department of the autonomic nervous system, increases adrenal secretion of adrenaline, has a moderate diuretic effect.

    Pharmacokinetics:

    After parenteral administration calcium gluconate with blood flow evenly distributed in all tissues and organs. In blood plasma, about 45% of the drug is in combination with proteins. Penetrates through the placental barrier, enters the breast milk. It is excreted from the body mainly by the kidneys.

    Indications:

    Diseases accompanied by: hypocalcemia, increased permeability cell membranes, a violation of the conduction of nerve impulses in muscle tissue. Hypoparathyroidism (latent tetany, osteoporosis), metabolic disturbances of the vitamin D: rickets, (spasmophilia, osteomalacia), hyperphosphataemia in patients with chronic renal insufficiency.

    The increased need for calcium (pregnancy, lactation, the period of intensive growth of the organism), the lack of calcium in the diet, the violation of its exchange (post-menopausal).

    Enhanced excretion of calcium (prolonged bed rest, chronic diarrhea, secondary hypocalcemia, long-term use of diuretics and antiepileptic drugs, glucocorticosteroids).

    Bleeding of various etiologies; allergic diseases (serum sickness, urticaria, febrile syndrome, itching, itching dermatoses, reactions to medication administration and food intake, angioedema); dystrophic alimentary swelling, pulmonary tuberculosis, lead colic; eclampsia.

    Hyperkaliemic form of paroxysmal myoplegia.

    Contraindications:

    Hypersensitivity, hypercalcemia (calcium concentration should not exceed 12 mg% or 6 mEq / L) expressed hypercalciuria, nefrourolitiaz (calcium), sarcoidosis, simultaneous cardiac glycosides (risk of arrhythmias).

    Carefully:

    Dehydration, electrolyte disturbances (risk of hypercalcemia), diarrhea, malabsorption syndrome, calcium nefrourolitiaz (in history), a small hypercalciuria, moderate chronic renal failure, chronic heart failure, widespread atherosclerosis, hypercoagulation, in elderly patients, especially in the presence of one or more above mentioned states. For intramuscular injection - children's age (risk of necrosis).

    Before using the drug, you should consult your doctor.

    Pregnancy and lactation:

    It is possible to use during pregnancy and during breastfeeding according to the indications and under strict control of serum calcium concentration, since hypercalcemia negatively affects the fetus and the baby.

    Dosing and Administration:

    During treatment, the concentration of calcium in the serum should be carefully monitored.

    The drug is injected deeply intramuscularly, or intravenously slowly (within 2-3 minutes), or drip, to exclude the possibility of local irritation or necrosis in case of getting the drug into the perivascular tissue. Because of the risk of local irritation, intramuscular injections should be performed only if intravenous injection is not possible. Intramuscular injections must be done deep enough in the muscle, preferably in the gluteal region. For patients suffering from obesity, a longer needle should be chosen for safe insertion into the muscle, rather than in fatty tissue. If repeated injections are required, the injection site should be changed each time.

    Adults: deep intramuscularly, intravenously slowly (for 2-3 min) or drip 5-10 ml of 10% solution daily, every other day or 2 days (depending on the nature of the disease and the clinical condition of the patient). The subsequent doses are determined in accordance with the concentration of calcium in the blood serum.

    Children under 18 years: the dose and mode of administration depend on the degree of development of hypocalcemia, the nature and severity of the symptoms.

    Children, depending on age, the drug is administered in the following doses: up to 6 months - 0.1-1 ml; 7-12 months - 1-1.5 ml; 1 - 3 years - 1,5-2 ml; 4-6 years - 2 - 2.5 ml; 7-14 years - 3-5 ml; over 14 years - doses for adults.

    Children should not inject the drug intramuscularly because of the possible development of necrosis. It is recommended only slow intravenous injection or intravenous infusion after dilution, in order to achieve sufficiently low rates of administration and to exclude the possibility of local irritation or necrosis in case of accidental ingestion of the drug in perivascular tissue.

    For intravenous infusion, the drug is diluted 1:10 to 10 mg / ml with the following infusion solutions: 0.9% sodium chloride solution or 5% glucose solution. The rate of intravenous administration should not exceed 50 mg of calcium gluconate per minute.

    Elderly patients

    Data indicative of unfavorable calcium intolerance to gluconate in elderly patients are not available, however, age-related changes in the body, such as renal dysfunction and metabolic slowdown, may require a dose reduction.

    Side effects:

    With intramuscular and intravenous administration, nausea, vomiting, diarrhea, bradycardia are possible.

    With intravenous administration, burning in the oral cavity, a sensation of fever, with a rapid intravenous injection - a decrease in blood pressure, arrhythmia, fainting, cardiac arrest can be observed.

    In places of intramuscular injection, necrosis may form.

    Overdose:

    Symptoms: the development of hypercalcemia, characterized by nausea, vomiting, severe weakness, thirst, drowsiness, disorientation, obscuration of consciousness, renal insufficiency. Hypercalcaemia of severe degree (calcium more than 3.4 mmol / l) poses a threat to life, due to increasing symptoms, renal failure, dehydration, and requires immediate infusion therapy.

    Treatment: calcitonin intravenously drip, 5-10 ME per kg of body weight per day (the drug is diluted in 500 ml of isotonic sodium chloride solution, injected for 6 hours).
    Interaction:

    Before filling with the calcium solution of the gluconate of the syringe, the syringe should not contain the remains of ethyl alcohol, since in the presence of the latter calcium gluconate precipitates.

    Pharmaceutically incompatible with carbonates, salicylates, sulfates (forms insoluble or hardly soluble calcium salts with them). Forms insoluble complexes with antibiotics of the tetracycline series, reducing their antibacterial effect.

    Reduces the effect of blockers of "slow" calcium channels (intravenous calcium gluconate before or after verapamil reduces its hypotensive effect, but has little effect on its antiarrhythmic effect).

    With simultaneous application with quinidine, it is possible to slow intraventricular conduction and increase the toxicity of quinidine. It is not recommended to use calcium gluconate during treatment with cardiac glycosides (cardiotoxic effect of cardiac glycosides is possible).

    When combined with thiazide diuretics can increase hypercalcemia.

    Reduces the effect of calcitonin in hypercalcemia.

    Reduces the bioavailability of phenytoin.

    Special instructions:

    The preparation is heated to the body temperature before administration. Adults and children are injected slowly, for 2-3 minutes.

    With intravenous administration, a feeling of heat can be felt throughout the body, which quickly passes.

    The patient at the time of injection should be in a prone position under close monitoring of heart rate and ECG.

    Because of the risk of local irritation, intramuscular injections should be performed only if intravenous injection is not possible. Intramuscular injections must be performed deep enough in the muscle, preferably in the gluteal region. For patients suffering from obesity, a longer needle should be chosen for safe insertion into the muscle, rather than in fatty tissue. If repeated injections are required, the injection site should be changed each time.

    During treatment, the concentration of calcium in the serum should be carefully monitored.

    With the intravenous administration of calcium gluconate, in exceptional cases, patients receiving cardiac glycosides need cardiac monitoring and conditions should be provided for the immediate treatment of cardiac complications such as severe arrhythmias.

    Calcium salts should be used with caution and only after careful determination of indications in patients with nephrocalcinosis, heart disease, sarcoidosis (Beck's disease), in elderly patients.

    Impaired renal function may be associated with hypercalcemia and secondary hyperparathyroidism. Therefore, in patients with impaired renal function, parenteral calcium administration should be administered only after a careful determination of the indications, while controlling the calcium-phosphate balance.

    When used simultaneously with other medicines, a doctor's supervision is required.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment period, care must be taken when driving a car and engaging in potentially dangerous activities that require concentration and speed of psychomotor reactions.

    Form release / dosage:

    Solution for intravenous and intramuscular injection 100 mg / ml.

    Packaging:

    By 5 ml or 10 ml into ampoules of borosilicate glass of hydrolytic class I with a ring of fracture or break point.

    5 or 10 ampoules per contour cell package.

    On 1 or 2 contour acheikova packing with the instruction on application in a pack from a cardboard.

    Storage conditions:

    In the dark place at a temperature of 20 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002146
    Date of registration:16.07.2013
    Expiration Date:16.07.2018
    The owner of the registration certificate:NOVOSIBHIMFARM, OJSC NOVOSIBHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.11.2017
    Illustrated instructions
      Instructions
      Up